International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Int J Gynecol Cancer · ISSN (e) 1525-1438 · 114 papers in corpus
review 2026
doi:10.1016/j.ijgc.2026.104742 ·PMID:42173755

Deep infiltrating endometriosis and oncologic radical pelvic surgeries pose a significant risk of nerve damage. A thorough understanding of pelvic anatomy is essential for surgical precision and to avoid neurological complications or dysfun…

2026
doi:10.1016/j.ijgc.2026.104676 ·PMID:42056783

Tubo-ovarian cancer represents the most lethal gynecologic malignancy, and its burden is compounded by the absence of effective screening and the substantial lifetime risk carried by women with germline BRCA1 or BRCA2 pathogenic variants. W…

2026
doi:10.1016/j.ijgc.2025.102769 ·PMID:41274017

Opportunistic salpingectomy reduces ovarian cancer risk. To examine heterogeneity among physicians in their adoption of opportunistic salpingectomy in hysterectomy practice, we identified 33,401 non-pregnant patients aged 18 to 49 years in …

2025
doi:10.1016/j.ijgc.2025.101638 ·PMID:39914268

Mesonephric and mesonephric-like adenocarcinomas of the gynecologic tract are a rare subset of gynecologic tumors that are frequently associated with the presence of somatic KRAS mutations. Owing to their rare nature and ability to arise in…

article 2025
doi:10.1016/j.ijgc.2025.101990 ·PMID:40685312

OBJECTIVE: Mesonephric-like adenocarcinoma is a rare, aggressive ovarian cancer subtype, newly classified by the World Health Organization in 2020. This study examines the clinical, ultrasound, pathological features, and survival outcomes o…

other 2025
doi:10.1016/j.ijgc.2025.101979 ·PMID:40639279

The presence of Fusobacterium nucleatum has been associated with gynecological disorders, namely endometriosis and pregnancy complications; however, its role in endometrial cancer remains unexplored. This study aimed to assess the presence …

other 2025
doi:10.1016/j.ijgc.2024.100025 ·PMID:39878280

OBJECTIVE: Several reproductive factors are associated with ovarian cancer risk but the association with survival is less clear. The main aim was to examine the impact of pre-diagnostic reproductive factors on long-term ovarian cancer survi…

article 2025
doi:10.1016/j.ijgc.2025.101634 ·PMID:39955191

OBJECTIVE: This study aimed to describe 2 types of endometriosis-associated ovarian cancer: those with transitional elements (atypical endometriosis and borderline tumors) termed endometriosis-correlated or incidental benign endometriosis v…

article 2024
doi:10.1136/ijgc-2023-005139 ·PMID:38531540

OBJECTIVE: To compare survival outcomes and patterns of recurrence between endometriosis-associated ovarian cancer patients and non-endometriosis-associated ovarian cancer patients. METHODS: This retrospective study included data of consec…

2024
doi:10.1136/ijgc-2024-005332 ·PMID:38862154

ObjectivesPrimary mucinous ovarian carcinoma represents 3% of ovarian cancers and is typically diagnosed early, yielding favorable outcomes. This study aims to identify risk factors, focussing on the impact of age and ethnicity on survival …

2024
doi:10.1136/ijgc-2023-005194 ·PMID:38508587

ObjectivesTo investigate the association of molecular and pathologic factors with concurrent or recurrent ovarian disease to guide ovarian preservation in endometrioid endometrial cancer.MethodsPatients with endometrial cancer ≤50 years of …

article 2024
doi:10.1016/j.ijgc.2024.100055 ·PMID:39971440
2024
doi:10.1136/ijgc-2023-004583 ·PMID:38438171
erratum 2023
doi:10.1136/igc.0000000000001137corr1 ·PMID:37011926
2023
doi:10.1136/ijgc-2023-004429 ·PMID:37127326

In 2018, the European Society of Gynecological Oncology (ESGO) jointly with the European Society for Radiotherapy and Oncology (ESTRO) and the European Society of Pathology (ESP) published evidence-based guidelines for the management of pat…

article 2023
doi:10.1136/ijgc-2022-004151 ·PMID:37543373

A 51-year-old pre-menopausal patient underwent a laparoscopic ovarian cystectomy for persistent bilateral cysts. Pathology analysis revealed borderline endometrioid tumors on both ovaries[1][1] ([Figures 1–4][2]). A secondary review confirm…

meta-analysis 2023
doi:10.1136/ijgc-2022-004014 ·PMID:36914172

OBJECTIVE: In endometrial carcinoma patients, sentinel lymph node bilateral mapping fails in 20-25% of cases, with several factors affecting the likelihood of detection. However, pooled data about predictive factors of failure are lacking. …

2023
doi:10.1136/ijgc-2022-003363 ·PMID:36170996
2023
doi:10.1136/ijgc-2022-004213 ·PMID:36958755

The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) …

2023
doi:10.1136/ijgc-2022-004038 ·PMID:36898699

ObjectiveThe aim of this study was to analyze the clinical and reproductive outcomes of patients treated with myomectomy who were histologically diagnosed with uterine smooth muscle tumor of uncertain malignant potential (STUMP).MethodsPati…

other 2022
doi:10.1136/ijgc-2022-003565 ·PMID:35948366

OBJECTIVE: Obturator nerve injury can occur as a complication of gynecologic surgeries, occurring most frequently in patients with endometriosis and genitourinary malignancies. The resulting injury causes paresthesia and major weakness in a…

2022
doi:10.1136/ijgc-2022-003911 ·PMID:36384753

ObjectiveOvarian cancer is known for its poor prognosis, which is mainly due to the lack of early symptoms and adequate screening options. In this study we evaluated whether mutational analysis in cervicovaginal and endometrial samples coul…

2022
doi:10.1136/ijgc-2022-003935 ·PMID:36368707

ObjectiveWe sought to describe clinicopathologic and treatment factors associated with oncologic outcomes in patients with early-stage ovarian clear cell carcinoma undergoing complete staging and in a sub-set of these patients undergoing fe…

2022
doi:10.1136/ijgc-2022-003882 ·PMID:36368706

ObjectiveTo evaluate the efficacy and safety of gonadotropin-releasing hormone agonist (GnRHa) combined with a levonorgestrel-releasing intrauterine device (LNG-IUD) or aromatase inhibitor (letrozole) in women with endometrial carcinoma or …

2022
doi:10.1136/ijgc-2022-003544 ·PMID:35667673